

As required under MAS Notice 637 and in line with Basel III requirements, **Tables 1 and 2** are mandatory disclosures on Regulatory Capital using prescribed templates.

**Table 1** shows the reconciliation between the Group's published consolidated balance sheet and the regulatory capital components. The balance sheet is expanded to identify and map to the regulatory capital components as set out in Table 2 (in the column "Reference").

The scope of consolidation for accounting and regulatory purposes is similar, except that subsidiaries which carry out insurance business are not consolidated for regulatory purpose. The list of the Group's major insurance subsidiaries can be found in the Annual Report. As at 31 Mar 2016, the total assets or total equities of each of these subsidiaries were less than S\$1 billion.

**Table 1 - Reconciliation of Balance Sheet to Regulatory Capital as at 31 Mar 2016**

S\$ million	Balance sheet as per published financial statements	Under regulatory scope of consolidation	Reference
<b>Equity</b>			
Share capital and other capital	5,149		
of which: Paid-up ordinary shares	3,803	3,803	A
of which: AT1 capital instruments	1,346	1,346	B
Retained earnings	16,188	16,083	C
Other reserves	9,292	9,256	D
Equity attributable to equity holders of the Bank	30,629		
Non-controlling interests	159		
of which: Transitional: Ineligible surplus NCI of bank subsidiaries		0	E1
of which: NCI that meets criteria for inclusion in			
- CET1 capital		11	E2
- AT1 capital		2	E3
- T2 capital		3	E4
<b>Total equity</b>	<b>30,788</b>		
<b>Liabilities</b>			
Deposits and balances of banks	10,990		
Deposits and balances of non-bank customers	254,779		
Bills and drafts payable	492		
Other liabilities	11,955		
Debts issued	20,662		
of which: Transitional: Ineligible T2 capital instruments	2,865	2,865	F1
of which: T2 capital instruments	2,548	2,548	F2
<b>Total liabilities</b>	<b>298,877</b>		
<b>Assets</b>			
Cash, balances and placements with central banks	36,663		
Singapore Government treasury bills and securities	6,796		
Other government treasury bills and securities	13,175		
Trading securities	2,147		
Placements and balances with banks	33,244		
Loans to non-bank customers	205,576		
of which: Provisions eligible for inclusion in T2 capital		1,025	G
Investment securities <sup>1</sup>	10,910		
of which: Investment in PE/VC exceeding 20% shareholding or holding period		56	H
Other assets <sup>1</sup>	13,070		
of which: Amount related to deferred tax assets (net of deferred tax liabilities, where permissible)		279	I
Investment in associates and joint ventures <sup>1</sup>	1,093		
of which: Amount related to goodwill		1	J1
Investment properties	1,096		
Fixed assets	1,753		
Intangible assets	4,142		
of which: Amount related to goodwill		4,142	J2
Investments approved under s32 of the Banking Act and insurance subsidiaries			
of which: Ordinary shares subject to threshold deduction		175	K1
of which: AT1 capital instruments		4	K2
Indirect investments in own capital instruments	-	1	L
<b>Total Assets</b>	<b>329,666</b>		

Abbreviation: CET1: Common Equity Tier 1; AT1: Additional Tier 1; T2: Tier 2; PE/VC: Private Equity and Venture Capital

Note:

<sup>1</sup> This includes investments approved under s32 of the Banking Act such as equity investments in investee companies exceeding 10% shareholding

**Table 2** lists the regulatory capital components and the corresponding regulatory adjustments. The columns: (a) 'Amount' refers to components of capital calculated in accordance with MAS Notice 637, effective 1 Jan 2013, (b) 'Amount subject to Pre-Basel III Treatment' refers to components of capital that are on transitional arrangement, otherwise would be fully applied towards the relevant tier of capital, and (c) 'Source' provides link to Table 1 by way of alphabetic / alphanumeric references, and cross-reference within the table by way of row number. Regulatory adjustments that are deducted against capital are reflected as positive numbers. Amounts less than \$500,000 in absolute terms are shown as "0".

**Table 2 - Capital Components as at 31 Mar 2016**

	S\$ million	Amount	Amount subject to Pre-Basel III Treatment	Source
<b>Common Equity Tier 1 capital: instruments and reserves</b>				
1	Paid-up ordinary shares and share premium (if applicable)	3,803		A
2	Retained earnings	16,083		C
3 <sup>#</sup>	Accumulated other comprehensive income and other disclosed reserves	9,256		D
4	Directly issued capital subject to phase out from CET1 (only applicable to non-joint stock companies)	-		
5	Minority interest that meets criteria for inclusion	12	(0)	E1+E2, -E1
6	<b>Common Equity Tier 1 capital before regulatory adjustments</b>	29,154		
<b>Common Equity Tier 1 capital: regulatory adjustments</b>				
7	Valuation adjustment pursuant to Part VIII of MAS Notice 637	-		
8	Goodwill, net of associated deferred tax liability	2,486	1,657	J1+J2
9 <sup>#</sup>	Intangible assets, net of associated deferred tax liability	-	-	
10 <sup>#</sup>	Deferred tax assets that rely on future profitability	167	111	I
11	Cash flow hedge reserve	-	-	
12	Shortfall of TEP relative to EL under IRBA	-	-	
13	Increase in equity capital resulting from securitisation transactions	-	-	
14	Unrealised fair value gains/losses on financial liabilities and derivative liabilities arising from changes in own credit risk	-	-	
15	Defined benefit pension fund assets, net of associated deferred tax liability	-		
16	Investments in own shares	1		L
17	Reciprocal cross-holdings in ordinary shares of financial institutions	-		
18	Capital investments in ordinary shares of unconsolidated financial institutions in which Reporting Bank does not hold a major stake	-		
19 <sup>#</sup>	Investments in ordinary shares of unconsolidated major stake companies approved under s32 of Banking Act (including insurance subsidiaries) (amount above 10% threshold)	105	70	K1
20 <sup>#</sup>	Mortgage servicing rights (amount above 10% threshold)	-		
21 <sup>#</sup>	Deferred tax assets arising from temporary differences (amount above 10% threshold, net of related tax liability)	-		
22	Amount exceeding the 15% threshold	-		
23 <sup>#</sup>	of which: investments in ordinary shares of unconsolidated major stake companies approved under s32 of Banking Act (including insurance subsidiaries)	-		
24 <sup>#</sup>	of which: mortgage servicing rights	-		
25 <sup>#</sup>	of which: deferred tax assets arising from temporary differences	-		
26	National specific regulatory adjustments	34		
26A	PE/VC investments in the form of ordinary shares, in excess of 20% of such capital investments	33	22	H
26B	PE/VC investments held beyond the relevant holding periods set out in MAS Notice 630	1	1	H
26C	Capital deficits in subsidiaries and associates that are regulated financial institutions	-	-	
26D	Any other items which the Authority may specify	-		
27	Regulatory adjustments applied in calculation of CET1 Capital due to insufficient AT1 Capital to satisfy required deductions	424		shortfall of row 36 over row 43
28	<b>Total regulatory adjustments to CET1 Capital</b>	3,217		
29	<b>Common Equity Tier 1 capital (CET1)</b>	<b>25,937</b>		
<b>Additional Tier 1 capital: instruments</b>				
30	AT1 capital instruments and share premium (if applicable)	1,346		B
31	of which: classified as equity under the Accounting Standards	1,346		
32	of which: classified as liabilities under the Accounting Standards	-		
33	Transitional: Ineligible capital instruments (pursuant to paragraphs 6.5.3 and 6.5.4)	-		
34	AT1 capital instruments issued by fully-consolidated subsidiaries that meet criteria for inclusion	2		E3
35	of which: instruments issued by subsidiaries subject to phase out	-		
36	<b>Additional Tier 1 capital before regulatory adjustments</b>	1,348		
<b>Additional Tier 1 capital: regulatory adjustments</b>				
37	Investments in own AT1 capital instruments	0		L
38	Reciprocal cross-holdings in AT1 capital instruments of financial institutions	-		
39	Capital investments in AT1 capital instruments of unconsolidated financial institutions in which Reporting Bank does not hold a major stake	-		

**Table 2 - Capital Components as at 31 Mar 2016**

	S\$ million	Amount	Amount subject to Pre-Basel III Treatment	Source
40 <sup>#</sup>	Investments in AT1 capital instruments of unconsolidated major stake companies approved under s32 of Banking Act (including insurance subsidiaries)	3	1	K2
41	National specific regulatory adjustments	1,769		
41A	PE/VC investments in the form of AT1 capital instruments, in excess of 20% of such capital investments	-	-	
41B	Any other items which the Authority may specify	-		
41C	Regulatory adjustments applied to AT1 Capital in respect of amounts subject to pre-Basel III treatment	1,769		
	of which: Goodwill, net of associated deferred tax liability	1,657		row 8 at 40%
	of which: Intangible assets, net of associated deferred tax liability	-		
	of which: Deferred tax assets that rely on future profitability	111		row 10 at 40%
	of which: Cash flow hedge reserve	-		
	of which: Increase in equity capital resulting from securitisation transactions	-		
	of which: Unrealised fair value gains/losses on financial liabilities and derivative liabilities arising from changes in own credit risk	-		
	of which: Shortfall of TEP relative to EL under IRBA	-		
	of which: PE/VC investments in the form of ordinary shares, in excess of 20% of such capital investments	-		
	of which: PE/VC investments held beyond the relevant holding periods set out in MAS Notice 630	-		
	of which: Capital deficits in subsidiaries and associates that are regulated financial institutions	-		
	of which: Investments in ordinary shares of unconsolidated major stake companies approved under s32 of Banking Act (incl insurance subsidiaries)	-		
	of which: PE/VC investments in the form of Tier 2 capital instruments, in excess of 20% of such capital investments	-		
	of which: Investments in Tier 2 capital instruments of unconsolidated major stake companies approved under s32 of Banking Act (incl insurance subsidiaries)	-		
42	Regulatory adjustments applied in calculation of AT1 Capital due to insufficient Tier 2 Capital to satisfy required deductions	-		
43	<b>Total regulatory adjustments to Additional Tier 1 capital</b>	1,772		
44	<b>Additional Tier 1 capital (AT1)</b>	-		floored at zero
45	<b>Tier 1 capital (T1 = CET1 + AT1)</b>	<b>25,937</b>		
	<b>Tier 2 capital: instruments and provisions</b>			
46	Tier 2 capital instruments and share premium (if applicable)	2,548		F2
47	Transitional: Ineligible capital instruments (pursuant to paragraphs 6.5.3 and 6.5.4)	2,865		F1
48	Tier 2 capital instruments issued by fully-consolidated subsidiaries that meet criteria for inclusion	3		E4
49	of which: instruments issued by subsidiaries subject to phase out	-		
50	Provisions	1,025		G
51	<b>Tier 2 capital before regulatory adjustments</b>	6,441		
	<b>Tier 2 capital: regulatory adjustments</b>			
52	Investments in own Tier 2 instruments	-		L
53	Reciprocal cross-holdings in Tier 2 capital instruments of financial institutions	-		
54	Capital investments in Tier 2 capital instruments of unconsolidated financial institutions in which Reporting Bank does not hold a major stake	-		
55 <sup>#</sup>	Investments in Tier 2 capital instruments of unconsolidated major stake companies approved under s32 of Banking Act (including insurance subsidiaries)	-	-	
56	National specific regulatory adjustments	93		
56A	PE/VC investments in the form of Tier 2 capital instruments, in excess of 20% of such capital investments	-	-	
56B	Any other items which the Authority may specify	-		
56C	Regulatory adjustments applied to Tier 2 Capital in respect of amounts subject to pre-Basel III treatment	93		
	of which: Shortfall of TEP relative to EL under IRBA	-		
	of which: PE/VC investments in the form of ordinary shares, in excess of 20% of such capital investments	22		row 26A at 40%
	of which: PE/VC investments held beyond the relevant holding periods set out in MAS Notice 630	1		row 26B at 40%
	of which: Capital deficits in subsidiaries and associates that are regulated financial institutions	-		
	of which: Investments in ordinary shares of unconsolidated major stake companies approved under s32 of Banking Act (incl insurance subsidiaries)	70		row 19 at 40%
	of which: PE/VC investments in the form of AT1 capital instruments, in excess of 20% of such capital investments	-		

**Table 2 - Capital Components as at 31 Mar 2016**

	S\$ million	Amount	Amount subject to Pre-Basel III Treatment	Source
	of which: Investments in AT1 capital instruments of unconsolidated major stake companies approved under s32 of Banking Act (incl insurance subsidiaries)	1		row 40 at 20%
57	<b>Total regulatory adjustments to Tier 2 capital</b>	93		
58	<b>Tier 2 capital (T2)</b>	<b>6,348</b>		
59	<b>Total capital (TC = T1 + T2)</b>	<b>32,285</b>		
60	<b>Total risk weighted assets</b>	<b>201,934</b>		
	<b>Capital ratios (as a percentage of risk weighted assets)</b>			
61	<b>Common Equity Tier 1 CAR</b>	<b>12.8%</b>		
62	<b>Tier 1 CAR</b>	<b>12.8%</b>		
63	<b>Total CAR</b>	<b>16.0%</b>		
64	Bank-specific buffer requirement	7.169%		
65	of which: capital conservation buffer requirement	0.625%		
66	of which: bank specific countercyclical buffer requirement <sup>1</sup>	0.044%		
67	of which: G-SIB buffer requirement (if applicable)	-		
68	Common Equity Tier 1 available to meet buffers	4.2%		
	<b>National minima</b>			
69	Minimum CET1 CAR	6.5%		
70	Minimum Tier 1 CAR	8.0%		
71	Minimum Total CAR	10.0%		
	<b>Amounts below the thresholds for deduction (before risk weighting)</b>			
72	Investments in ordinary shares, AT1 capital and Tier 2 capital of unconsolidated financial institutions in which the bank does not hold a major stake	418		
73	Investments in ordinary shares of unconsolidated major stake companies approved under s32 of Banking Act (including insurance subsidiaries)	2,647		
74	Mortgage servicing rights (net of related tax liability)	-		
75	Deferred tax assets arising from temporary differences (net of related tax liability)	-		
	<b>Applicable caps on the inclusion of provisions in Tier 2</b>			
76	Provisions eligible for inclusion in Tier 2 in respect of exposures subject to standardised approach (prior to application of cap)	376		
77	Cap on inclusion of provisions in Tier 2 under standardised approach	244		row 50
78	Provisions eligible for inclusion in Tier 2 in respect of exposures subject to internal ratings-based approach (prior to application of cap)	1,120		
79	Cap for inclusion of provisions in Tier 2 under internal ratings-based approach	781		row 50
	<b>Capital instruments subject to phase-out arrangements (only applicable between 1 Jan 2013 and 1 Jan 2022)</b>			
80	Current cap on CET1 instruments subject to phase out arrangements	-		
81	Amount excluded from CET1 due to cap (excess over cap after redemptions and maturities)	-		
82	Current cap on AT1 instruments subject to phase out arrangements	1,289		
83	Amount excluded from AT1 due to cap (excess over cap after redemptions and maturities)	-		
84	Current cap on T2 instruments subject to phase out arrangements	3,128		
85	Amount excluded from T2 due to cap (excess over cap after redemptions and maturities)	-		

# These elements are subject to a more conservative definition relative to those set out under the Basel III capital standards.

Note:

<sup>1</sup> The Group's countercyclical buffer (CCyB) is computed as the weighted average of effective CCyB in jurisdictions to which the Group has private sector exposures. As at 31 March 2016, the Group has private sector exposures to Hong Kong and Sweden, whose effective country-specific CCyB is 0.625% for the year of 2016. The weightings applied to Hong Kong and Sweden exposures are 7% and 0% respectively.